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ABSTRACT		Neuroendocrine	 tumors	metastazing	 to	 the	breast	are	exceedingly	 rare	and	account	 for	 less	 than	2%	of	tumors	 in	 the	breasts.	They	are	usually	 initially	diagnosed	as	primary	breast	carcinoma	and	 the	correct	treatment	is	delayed.	Accurate	preoperative	identification	of	the	tumor	will	result	in	the	avoidance	a	major	surgery	 including	 axillary	 lymphnodal	 clearance.	We	here	 report	 a	 case	of	 a	metastatic	neuroendocrine	deposit	in	the	breast	following	a	Laparoscopic	Anterior	Resection(for	neuroendocrine	tumor	of	rectum)	and	Right	Hepatectomy	(for	synchronous	liver	metastasis).	
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INTRODUCTION	Breast	 metastases	 from	 non-mammary	 malignant	neoplasms	are	rare,	accounting	for	less	than	2%	of	all	breast	 tumors.	 Neuroendocrine	 metastases	 to	 the	breast	 are	 clinically,	 radiologically,	 and	pathologically	 very	 easily	 mistaken	 for	 a	 primary	breast	 carcinoma.	 The	 proper	 recognition	 of	 such	tumors	 is	 very	 important	 owing	 to	 the	 different	clinical	 management	 of	 these	 patients.	 We	 here	report	 a	 case	 of	 metastatic	 breast	 NET	 originating	from	a	primary	rectal	neuroendocrine	tumor.	
CASE	PRESENTATION	A	39-year-old	lady	who	had	undergone	a	laproscopic	anterior	 resection	 	 and	 a	 right	 hepatectomy	 for	 a	
neuroendocrine	 tumor	 2	 years	 back	 with	 liver	metastasis	 presented	 with	 a	 palpable	 mass	 in	 the	right	breast,	associated	with	mild	pain.	There	was	no	history	of	nipple	discharge	,	fever	or	change	in	colour	of	the	skin	over	the	lump.	No	palpable	axillary	lymph	nodes	bilaterally.			
 
Figure 1: Elastography with mammography of left 
breast showing hypoechoic lesion 17x 10 mm with 
distal enhancement and intense internal vascularity	A	review	of	her	history	demonstrated	that	she	had	a	rectal	 neuroendocrine	 tumor,	 which	 was	 resected	elsewhere	by	laparoscopic	Anterior	resection	2	years	ago	 along	 with	 right	 hepatectomy	 for	 synchronous	liver	metastases.	 The	 preoperative	 CECT	 	 abdomen	showed	 low	 rectal	 polypoidal,	 enhancing	 eccentric	tumour	 about	 75	 mm	 from	 anorectal	 angle,	 with	perirectal	 fat	 stranding	 and	 multiple	 mesorectal	nodes	and	right	internal	iliac	nodes	,	multiple	arterial	enhancing	lesions	in	liver	largest	in	segment	6	and	7	–suggestive	 of	 metastases	 [T3N2M1].	 Preoperative	colonoscopy	 revealed	 large	 polypoidal	 friable	mass	measuring	 3.5	 cm	 with	 wide	 base	 causing	 partial	
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luminal	 obstruction	 8	 cm	 from	 anal	 verge,	 rest	 of	colonic	mucosa	and	vascular	patterns	were	normal.	Only	 the	 pathology	 report	 was	 available	 which	showed	 grade	 2	 well	 differentiated,	 strong	chromogranin	ad	synaptophysin	positive		NET		,	7/26	nodes	were	positive,	Ki	67%		was	5,	lymphovascular	invasion	was	present,	and	no	histopathology	material	could	be	retrieved.	At	 present	 the	 mammogram	 (Figure 1)	 revealed	 a	well-circumscribed	mass	 that	measured	1.7	x	1	cm.	Her	 FNAC	 showed	 High-grade	 carcinoma.	 A	 trucut	biopsy	with	IHC	showed	features	consistent	with	NET	metastases.	 A	 GA	 68	 DOTATAC	 PET	 SCAN	 showed	somatostatin	receptor	positivity	(Figure 2).	After	 consent	 a	 lumpectomy	 was	 performed	 and	microscopic	evaluation	showed	multiple	linear	cores	of	 breast	 parenchyma	 showing	 an	 invasive	 tumor	arranged	in	trabaculae,	nests,	sheets	and	perivascular	pseudorossettes.	 The	 tumor	 cells	 revealed	 round	hyperchromatic	 nuclei	 with	 inconspicuous	 nucleoli	and	 a	 moderate	 degree	 of	 eosinophilic	 cytoplasm	(Figure 3)	 No	 evidence	 of	 ductal	 carcinoma	 in	 situ	could	be	identified.	Immunohistochemical	analysis	of	the	same	showed	that	the	tumor	cells	were	strongly	positive	for	the	neuroendocrine	markers,	cytokertin	(AE1	 /AE3)	 and	 synaptophysin	 ,	 negative	 for	 ER	receptors	 and	 chromogranin	 A.	 Mib	 proliferative	index	 is	 approximately	 30-35	 %	 in	 the	 hotspots	(Figure 4,	Figure 5,	Figure 6)	
 
Figure 2: Left breast- somatostatin receptor positive 
small well defined enhancing soft tissue density lesion 
in upper medial quadrant	
 
Figure 3: Breast biopsy showing a tumor with neuro-
endocrine differentiation	
 
Figure 4: Synaptophysin (Neuroendocrine marker) 
strongly positive in the tumor cells. 
 
Figure 5: The tumor cells strongly express cytokeratin 
CK (AE1-AE3) 
 
Figure 6: Tumor cells are negative for Estrogen recep-
tors 
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Figure 7: Somatostatin receptor positive ill defined 
heterogenously enhancing soft tissue density lesion in 
presacral region on right side - A deposit Hence,	the	diagnosis	of	breast	metastatic	NET	from	a	primary	 rectal	 tumor	 was	 thus	 made.	 She	 did	 not	show	 symptoms	 of	 carcinoid	 syndrome.	 She	 was	treated	with	standard	cytotoxic	chemotherapy	using	a	combination	of	5-fluorouracil	(5-FU),	dacarbazine,	and	 epirubicin.	 However,	 this	 did	 not	 result	 in	 any	radiological	response.	Hence	she	was	started	on	everolimus	5	mg	once	daily,	this	did	result	in	some	radiological	response.	The	 rest	 of	 the	 breast	 showed	 no	 evidence	 of	microcalcification.	 Follow	 up	 PET	 also	 revealed	 a	heterogeneously	 enhancing	 lobulated	 pre-sacral	mass	measuring	3.7	x	2.5	cm,	which	was	somatostatin	receptor	positive.	CT	guide	Fine	needle	aspiration	of	the	 pre-sacral	 mass	 confirmed	 a	 neuroendocrine	tumour	consistent	with	tumor	recurrence	(Figure 7)	Her	general	condition	was	better	at	discharge	and	she	was	managed	with	T.Everolimus	5	mg	daily	on	follow	up.	
DISCUSSION	AND	CONCLUSIONS	A	literature	review	revealed	that	fewer	than	40	cases	of	metastatic	breast	NET	have	been	described	to	date	with	 the	 commonest	 site	 of	 origin	 being	 the	 small	bowel(1).	 A	 metastatic	 breast	 NET	 can	 be	 easily	mistaken	 for	primary	 carcinoma	of	 the	breast.	This	may	 potentially	 be	 detrimental	 if	mastectomy	with	dissection	of	axillary	lymphnodes	is	performed.		Metastatic	breast	NET	may	present	clinically	as	single	or	 multiple	 well-circumscribed	 lumps,	 with	 a	 firm	consistency.	 Radiologically	 they	 can	 appear	 as	 a	spiculated	 lesion	detected	on	mammography	and	 is	usually	 indistinguishable	 from	 primary	 invasive	
breast	 carcinoma,	 or	 as	 well-circumscribed	 lesions	that	can	mimic	fibroadenomas,	mucinous	carcinoma	or	 medullary	 carcinoma.	 Morphologic	 distinction	from	 primary	 ductal	 carcinomas	 is	 sometimes	difficult,	 however	 a	 plasmacytoid	 appearance,	 salt-and-pepper	 stippled	 chromatin,	 and	 inconspicuous	nucleoli	 on	 FNA	 should	 raise	 the	 possibility	 of	 a	neuroendocrine	origin.	Fishman	et	al,(2)	has	shown	in	a	review	61.5%	(8	of	13)	 patients	 with	 metastatic	 breast	 NETs	 were	initially	misdiagnosed	 as	 primary	 breast	 carcinoma	and	were	subjected	to	modified	radical	mastectomy.	Metastatic	 breast	 carcinoid	 can	 show	 estrogen	receptor	positivity,	creating	additional	problems.	Metastatic	 breast	 NET	 should	 be	 considered	 when	features	 such	 as	 a	 well-circumscribed	 lesion,	 the	absence	 of	 an	 intraductal	 component,	 and	 the	frequent	 presence	 of	 many	 lymphatic	 emboli	 are	present.	 Carcinomas	 of	 mammary	 origin	characteristically	strongly	express	CK7	and	will	not	express	CK20,	whereas	in	metastatic	carcinoid,	both	CK7	and	CK20	will	be	negative.	(3,4,5)	There	 are	 no	 clear	 guidelines	 on	 management	 of	metastatic	 neuroendocrine	 breast	 tumors.	 Initially	they	were	managed	with	 a	mastectomy	 along	with	axillary	 dissection,	 lumpectomy	 alone.	 There	 have	been	 significant	 developments	 in	 drug	 therapy	 of	advanced	 NETs.	 Long	 acting	 octreotide,	 m-TOR	inhibitors	 (everolimus),	 and	 VEGF	 tyrosine	 kinase	inhibitors	 (sunitinib)	 are	 becoming	 standard	treatments	 for	 patients	 with	 advanced	 NETs.	 So,	accurate	diagnosis	of	metastatic	NET	is	of	paramount	importance.	
CONCLUSION	We	 here	 wish	 to	 highlight	 the	 presence	 of	 a	neuroendocrine	metastasis	to	the	breast	in	order	to	highlight	not	all	tumors	arising	in	the	breast	are	that	of	primary	breast	carcinoma.	Accurate	preoperative	identification	of	the	tumor	will	result	in	the	avoidance	a	 major	 surgery	 including	 axillary	 lymph	 nodal	clearance.	With	the	advent	of	effective	drug	therapy	for	NET		is	now	possible	to	do	as	minimum	surgically	and	 still	 offer	 them	 a	 high	 quality	 of	 life	 even	 in	 a	metastatic	setting.		
REFERENCES	1. Mosunjac,	M.	B.,	 Kochhar,	 R.,	Mosunjac,	M.	 I.,	&	Lau,	S.	K.	(2004).	Primary	small	bowel	carcinoid	tumor	with	bilateral	breast	metastases:	report	of	2	 cases	 with	 different	 clinical	 presentations.	Archives	 of	 pathology	 &	 laboratory	 medicine,	128(3),	292-297.	2. Fishman,	A.,	Kim,	H.	S.,	Girtanner,	R.	E.,	&	Kaplan,	A.	 L.	 (1994).	 Solitary	 breast	 metastasis	 as	 first	
 Rajiv Maharaj et al., (2019) Int. J. Res. Can. Ther., 1(1), 8-11 
© Rubatosis Publications | International Journal of Research in Cancer Therapy 11  
manifestation	 of	 ovarian	 carcinoid	 tumor.	Gynecologic	oncology,	54(2),	222-226.	3. Geyer,	 H.	 L.,	 Viney,	 J.,	 &	 Karlin,	 N.	 (2010).	Metastatic	 carcinoid	 presenting	 as	 a	 breast	lesion.	Current	Oncology,	17(6),	73.	4. Gupta,	 C.,	Malani,	 A.	 K.,	 &	 Rangineni,	 S.	 (2006).	Breast	metastasis	 of	 ilial	 carcinoid	 tumor:	 case	report	 and	 literature	 review.	 World	 journal	 of	surgical	oncology,	4(1),	15.	5. Kanthan,	R.,	Negreiros,	F.,	&	Kanthan,	S.	C.	(2003).	Colonic	 carcinoid	 metastatic	 to	 the	 breast.	Archives	 of	 pathology	 &	 laboratory	 medicine,	127(10),	1373-1375.	
